ArticleRegenerative biomaterials2026
A novel polyester-drug nanoconjugate with subtype selectivity for high efficacy against PSMA-positive prostate cancer.
Article in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific membrane antigen (PSMA) positive prostate cancer (PCa) accounts for 80-90% cases. Docetaxel (DTX) is a first-line chemotherapy drug for metastatic castration resistant prostate cancer (mCRPC) and has exhibited promising efficacy. However, DTX usually causes severe side effects. To address this issue, we utilized short-chain poly(ethylene glycol) (PEG) as a monomer to prepare a water-soluble polyester, which was further modified by a PSMA ligand, 2-[3-[5-amino-1-carboxypentyl]-ureido]-pentanedioic acid (DCL) and covalently linked to DTX via a disulfide bond, resulting in a novel PSMA-targeting polyester-drug conjugate (PET-DCL-DTX). Here, the introduction of short-chain PEG into the polyester skeleton could enhance its hydrophilicity and drug-loading capacity. This conjugate is amphiphilic and forms a nanostructure via self-assembly in aqueous solution, allowing it to passively accumulate in tumor tissues via the enhanced permeability and retention (EPR) effect. Particularly, due to the specific recognition of DCL for PSMA, this nanoconjugate exerts a profound inhibitory effect on PSMA-positive PCa cells. After efficiently entering the cells, this nanoconjugate undergoes sensitive cleavage of the disulfide bond owing to the reductive molecules such as glutathione and releases DTX to suppress the PSMA-positive PCa development. Moreover, an improved safety of this nanoconjugate was observed
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.